What are Bispecific antibody-cytokine fusion drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bispecific antibody-cytokine fusion drugs are pharmacologic agents that share a common mechanism (typically targeting Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor). 0 are currently marketed, with 2 more in clinical development.

Bispecific antibody-cytokine fusion

0 marketed 2 in Phase 3

This page covers all Bispecific antibody-cytokine fusion drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor, FAP (fibroblast activation protein) and IL-2 receptor.

Targets

Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor · FAP (fibroblast activation protein) and IL-2 receptor

Phase 3 pipeline (2)

L19IL2 + L19TNF · Philogen S.p.A. · Oncology
L19IL2 + L19TNF is a bispecific antibody-cytokine fusion combination that targets tumor vasculature via the L19 antibody while delivering IL-2 and TNF directly to the tumor microenvironment.
FAP IL2V · Hoffmann-La Roche · Oncology
FAP IL2V is a bispecific immunotherapy that targets fibroblast activation protein (FAP) on cancer-associated fibroblasts while delivering interleukin-2 (IL-2) to activate anti-tumor immune responses.

Patent intelligence

bispecific antibody cytokine fusion patent landscape — aggregated cliff calendar, attackable patents, originator estates